益生菌联合屈螺酮炔雌醇片治疗多囊卵巢综合征的临床效果OA
Clinical effect of probiotics combined with Drospirenone and Ethinylestra-diol Tablets in the treatment of polycystic ovary syndrome
目的 探讨益生菌联合屈螺酮炔雌醇片治疗多囊卵巢综合征(PCOS)的临床效果.方法 选取 2023 年 6 月至2024 年6 月赣南医科大学第一附属医院收治的 78 例 PCOS 患者作为研究对象,按照随机数字表法将其分为试验组(39 例)与对照组(39 例).试验组患者口服屈螺酮炔雌醇片联合复合益生菌,对照组患者仅口服屈螺酮炔雌醇,共研究 3 个用药周期.比较两组患者的月经周期恢复率、停药后 6 个月疾病复发率、性激素、代谢参数及炎症因子水平、安全性.结果 试验组总有效率高于对照组,差异有统计学意义(P＜0.05);治疗后,试验组血清睾酮(T)、促黄体生成素/卵泡刺激素比值(LH/FSH)、胰岛素抵抗指数(HOMA-IR)、肿瘤坏死因子-α(TNF-α)水平及血脂谱中甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)水平均低于对照组,差异有统计学意义(P＜0.05);治疗后,试验组的促黄体生成素(LH)、促卵泡生成素(FSH)、空腹血糖(FPG)、空腹胰岛素(FINS)、总胆固醇(TC)、白细胞介素-6(IL-6)低于对照组,高密度脂蛋白胆固醇(HDL-C)水平高于对照组,差异有统计学意义(P＜0.05).停药后 6 个月,试验组疾病复发率低于对照组,差异有统计学意义(P＜0.05).两组患者不良反应总发生率比较,差异无统计学意义(P＞0.05).结论 益生菌联合屈螺酮炔雌醇片可协同改善 PCOS患者内分泌代谢紊乱及炎症状态,临床效果优于单药治疗,且安全性良好.
Objective To evaluate the clinical effect of probiotics combined with Drospirenone and Ethinylestradiol Tablets in patients with polycystic ovary syndrome(PCOS).Methods A total of 78 patients with PCOS admitted to First Affiliated Hospital of Gannan Medical University from June 2023 to June 2024 were selected as study objects,and they were divided into experimental group(39 cases)and control group(39 cases)by the random number table method.The experimental group received oral Drospirenone and Ethinylestradiol Tablets plus compound probiotics,while the control group received Drospirenone and Ethinylestradiol Tablets alone.The treatment lasted for 3 menstrual cycles.Menstrual cycle recovery rate,symptom recurrence rate at 6 months post-treatment,sex hormone levels,metabolic parameters,inflammatory factor levels,and safety were compared between the two groups.Results The total effective rate in the experimental group was higher than that in the control group,and the difference was statistically significant(P＜0.05).After treatment,serum testosterone(T),the luteinizing hormone/follicle-stimulating hormone ratio(LH/FSH),the homeostasis model assessment of insulin resistance index(HOMA-IR),tumor necrosis factor-α(TNF-α),triglycerides(TG),and low-density lipoprotein cholesterol(LDL-C)in the experimental group were lower than those of the control group,and the differences were statistically significant(P＜0.05).After the treatment,the levels of luteinizing hormone(LH),follicle-stimulating hormone(FSH),fasting plasma glucose(FPG),fasting insulin(FINS),total cholesterol(TC),and interleukin-6(IL-6)in the experimental group were lower than those in the control group,while the level of high-density lipoprotein cholesterol(HDL-C)was higher than that in the control group,the differences were statistically significant(P＜0.05).At the 6-month follow-up,the symptom recurrence rate in the experimental group was lower than that of the control group,and the difference was statistically significant(P＜0.05).There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion Probiotics combined with Drospirenone and Ethinylestradiol Tablets can synergistically improve the endocrine and metabolic disorders as well as the inflammatory state in patients with PCOS.The clinical effect is superior to that of single drug treatment,and the safety is also good.
温晓春;沈君菁;韩文玲;黄炉仁;刘欣
赣南医科大学第一附属医院妇产科,江西 赣州 341000赣南医科大学第一附属医院妇产科,江西 赣州 341000赣南医科大学第一附属医院妇产科,江西 赣州 341000赣南医科大学第一附属医院妇产科,江西 赣州 341000赣南医科大学第一附属医院妇产科,江西 赣州 341000
医药卫生
多囊卵巢综合征益生菌屈螺酮炔雌醇片胰岛素抵抗炎症因子
Polycystic ovary syndromeProbioticsDrospirenone and Ethinylestradiol TabletsInsulin resistanceInflam-matory factors
《中国当代医药》 2026 (13)
61-66,70,7
江西省卫生健康委科技计划项目(202310799).
评论